Literature DB >> 9699137

Incidence and impact of Clostridium difficile infection in the UK, 1993-1996.

M H Wilcox1, E T Smyth.   

Abstract

Questionnaires were sent to 360 UK medical microbiologists to determine the incidence of Clostridium difficile infection in the UK between 1993-1996, and to establish the current laboratory testing protocols. Replies were received from 104 laboratories (29% response rate), 86, 7, 4 and 3% of which are in England, Scotland, Wales and Northern Ireland, respectively. The laboratories serve a total of approximately 90,000 hospital beds (median 750). C. difficile testing was performed by 83% of the laboratories, and 52, 45 and 31% used toxin A +/- B kits, cell cytotoxicity, and culture +/- isolate toxigenicity testing methods, respectively. Forty-seven percent of laboratories only performed testing when specifically requested, 19% if antibiotic use was stated, 15% tested all diarrhoeal specimens, and 14% examined all specimens except those from infants and community patients. The annual totals of positive C. difficile reports and cases increased from 3132 to 12,775, and from 1576 to 8211, respectively, between 1993-1996. In 1993 C. difficile infection caused ward closures in 5% of hospitals but 16% in 1996. Antibiotic policy changes, due to C. difficile infection, occurred in 21% of hospitals in 1996 compared with only 4% in 1993. C. difficile infection appears to be increasing markedly in the UK with major implications on hospital inpatient activity. Wide variations in laboratory selection and testing methods are likely to be masking the true epidemiology of C. difficile infection, and consensus is required on optimal protocols.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699137     DOI: 10.1016/s0195-6701(98)90256-0

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  9 in total

1.  Choosing the right antibiotic. Right drug at right time in right dose saves lives.

Authors:  D Bihari
Journal:  BMJ       Date:  1999-10-02

2.  Underestimation of Clostridium difficile infection among clinicians: an international survey.

Authors:  M N Mavros; V G Alexiou; K Z Vardakas; K Tsokali; T A Sardi; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-27       Impact factor: 3.267

Review 3.  Acute gastroenteritis in children : what role for antibacterials?

Authors:  Nopaorn Phavichitr; Anthony Catto-Smith
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

5.  Type IV pili and the CcpA protein are needed for maximal biofilm formation by the gram-positive anaerobic pathogen Clostridium perfringens.

Authors:  John J Varga; Blair Therit; Stephen B Melville
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

6.  Assessing control bundles for Clostridium difficile: a review and mathematical model.

Authors:  Laith Yakob; Thomas V Riley; David L Paterson; John Marquess; Archie Ca Clements
Journal:  Emerg Microbes Infect       Date:  2014-06-18       Impact factor: 7.163

Review 7.  Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread.

Authors:  Archie C A Clements; Ricardo J Soares Magalhães; Andrew J Tatem; David L Paterson; Thomas V Riley
Journal:  Lancet Infect Dis       Date:  2010-06       Impact factor: 25.071

Review 8.  Systematic review of antimicrobial drug prescribing in hospitals.

Authors:  Peter Davey; Erwin Brown; Lynda Fenelon; Roger Finch; Ian Gould; Alison Holmes; Craig Ramsay; Eric Taylor; Phil Wiffen; Mark Wilcox
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

9.  Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model.

Authors:  Laith Yakob; Thomas V Riley; David L Paterson; Archie C A Clements
Journal:  BMC Infect Dis       Date:  2013-08-16       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.